Clinical Trial Update: Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating a rebeccamycin analog in adults with relapsed or refractory acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leuk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Rebeccamycin analog (rebeccamycin analog)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Status: COMPLETED